



**EVITRADE  
Health  
Systems  
Corporation**

## **EVITRADE Health Systems Corporation**

### **EVITRADE Health Systems Announces Doctor Supervised Clinical Study Site Set-Up Completed and Satisfactory Progress To-Date**

VANCOUVER, BC, Tuesday, October 11, 2016 – EVITRADE Health Systems Corp. (CSE:EVA, OTCQB: AXHLD) (the “Company” or “EVITRADE”) announces the completion of the clinical site set-up for the doctor supervised TULIP™ study. Over thirty patients have been selected and are now enrolled in the study.

Data acquired from the TULIP™ study is being processed and analyzed by our sponsored research program principal investigator. Preliminary data suggests that the TULIP™ system may benefit users interested in normalizing body weight, heart arrhythmia, blood pressure, and blood glucose.

"Our doctor-supervised TULIP™ study and sponsored research program is showing satisfactory progress in the early stages. We focus on thoroughly testing TULIP™ as an outpatient consumer health system in terms of scalability, interoperability, and marketability in a clinical and home setting." said Syd Au, Chairman and CEO.

#### **Contact:**

Sydney Au, Chairman & CEO

EVITRADE Health Systems Corporation  
(formerly Auxellence Health Corporation)

Email: [ceo@auxellence.com](mailto:ceo@auxellence.com)

Website: <http://www.auxellence.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

#### **About EVITRADE Health Systems Corporation (CSE: EVA, OTCQB: AXHLD)**

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online services for resolving common health problems.

The company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

The current focus is on the normalization of cardiometabolic power in terms of blood pressure, blood glucose, and body weight – and the monitoring of the physiological response to medical solicitations, mainly medication, diet, exercise, and lifestyle changes.

#### **About TULIP™**

The TULIP™ system is an online self-service intended for adults interested in normalizing blood pressure, heart rate and rhythm, blood glucose, and body weight. Measurement procedures, conditioning protocols, and session schedules are prescribed automatically from data acquired by the user's TULIP™ device – a



**EViTRADE  
Health  
Systems  
Corporation**

## **EViTRADE Health Systems Corporation**

blood pressure monitor with interactive protocols that can feed medical records and expert systems useful in testing, tracking and treating common health conditions.

The Tulip™ medical device has received Health Canada and CE Mark certifications.

### **Disclaimers – Forward Looking Statements**

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on [www.sedar.com](http://www.sedar.com), and <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.